Navigation Links
CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
Date:10/27/2008

ttp://www.ucb-group.com" target="_new">http://www.ucb-group.com for full prescribing information for CIMZIA.

Tuberculosis (frequently disseminated or extrapulmonary at clinical presentation), invasive fungal infections, and other opportunistic infections, have been observed in patients receiving CIMZIA. Some of these infections have been fatal. Anti-tuberculosis treatment of patients with latent tuberculosis infection reduces the risk of reactivation in patients receiving treatment with TNF blockers such as CIMZIA. However, active tuberculosis has developed in patients receiving CIMZIA whose tuberculin test was negative. Evaluate patients for tuberculosis risk factors and test for latent tuberculosis infection prior to initiating CIMZIA and during therapy. Initiate treatment of latent tuberculosis infection prior to therapy with CIMZIA. Monitor patients receiving CIMZIA for signs and symptoms of active tuberculosis, including patients who tested negative for latent tuberculosis infection. Consider anti-tuberculosis therapy prior to initiation of CIMZIA in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed.

Serious infections, sepsis, and cases of opportunistic infections, including fatalities, have been reported in patients receiving TNF blockers, including CIMZIA. Infections have been reported in patients receiving CIMZIA alone or in conjunction with immunosuppressive agents. Do not initiate treatment with CIMZIA in patients with active infections, including chronic or localized infections. Patients who develop a new infection while undergoing treatment with CIMZIA should be monitored closely. Discontinue administration of CIMZIA if a patient develops a serious infection. Exercise caution when considering the use of CIMZIA in patients with a history of recurrent infection, concomitant immunosuppressive therapy, or underlying conditions that may predispose them to infections, or
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
2. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
3. Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohns Disease
4. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
5. Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients
6. Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project
7. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)
8. Fralex provides update on timing of interim analysis results
9. Vanda Pharmaceuticals Provides Update on Iloperidone
10. Study Demonstrates That AHCC(R) Provides Immune Enhancement Against the West Nile Virus
11. Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... ,, PHILADELPHIA, Dec. 4 Teamster members employed ... are hard at work educating the public about the ... put Philadelphia,s blood supply at risk. More than ... picket line yesterday when their issues were ignored by ...
(Date:12/4/2009)... Corporation (Nasdaq: DYNT ) announced it has signed ... rehab supplies to Benchmark Physical Therapy with 65 clinics ... pleased to be named the sole-source supplier to Benchmark ... of sales and marketing at Dynatronics. "Benchmark is known ...
(Date:12/4/2009)... FOREST, Ill., Dec. 4 Hospira, Inc. (NYSE: ... medication delivery company, today announced the launch of its ... intravenous (I.V.) medications and solutions, and now offers a ... the award-winning, environmentally responsible VisIV product. The launch of ...
Breaking Medicine Technology:Striking Red Cross Workers Raise Public Awareness of Unsafe Working Conditions 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4The Healthcare Scoop Community Says 26apos 3BEye Care 26apos 3B 50306 1The Healthcare Scoop Community Says 26apos 3BEye Care 26apos 3B 50306 2The Healthcare Scoop Community Says 26apos 3BEye Care 26apos 3B 50306 3Access Pharmaceuticals Announces Commercial Launch of MuGard 28TM 29 in Greece by SpePharm 50303 1Access Pharmaceuticals Announces Commercial Launch of MuGard 28TM 29 in Greece by SpePharm 50303 2Access Pharmaceuticals Announces Commercial Launch of MuGard 28TM 29 in Greece by SpePharm 50303 3Air Methods Petitions NTSB for Reconsideration of Probable Cause Determination 50300 1Air Methods Petitions NTSB for Reconsideration of Probable Cause Determination 50300 2
(Date:12/6/2009)... feline DNA in virus , , SUNDAY, Dec. 6 (HealthDay News) ... be found in a tiger that lived thousands or millions ... the virus took on a bit of a tiger,s genetic ... in the virus to this day. That tiger, in fact, ... the virus that ultimately led to its infection of humans. ...
(Date:12/6/2009)... new study provides welcome news for patients with a ... , The condition is estimated to impact 62,000 Canadians ... abnormal clot forms in a vein and restricts the ... cases, the clot may detach from its point of ... causing a potentially fatal condition known as a pulmonary ...
(Date:12/5/2009)... NEW ORLEANS, Dec. 5 There have been significant ... leading experts continue to gain a better understanding of ... treatment options and provide patients with the best care. ... the American Society of Hematology explores optimal induction therapies ...
(Date:12/5/2009)... eliminate triggers, experts advise , , SATURDAY, Dec. 5 (HealthDay ... and asthma can have bad reactions to certain holiday ... sneezing and wheezing, according to the American College of ... allergic to live evergreens may choose to decorate with ...
(Date:12/5/2009)... unusual places, and to do everything from growing mushrooms, making wine to ... ... would have thought that your wine, water and vegetables would have come ... new line of turbines, for industry end users, not wind farms. ...
Breaking Medicine News(10 mins):Health News:AIDS May Date Back to Ancient Tiger 2Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8Health News:Keep Asthma, Allergies at Bay for the Holidays 2Health News:Distributor Announces New Applications for Wind Turbines 2Health News:Distributor Announces New Applications for Wind Turbines 3
... BETHESDA, Md., Feb. 3 The American College of Medical ... www.acmgfoundation.org . "The new ACMG Foundation website is not ... is but also to see first-hand how the initiatives of ... health through the translation of genetic discoveries into better patient ...
... the drug treatment of cancer pain in 2008 is valued ... released today by WWMR, Inc. The cancer pain market is ... the next decade. The increasing number of cancer pain ... the forecast period. Few of the many drugs in ...
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), ... Executive Officer, will present an update on the Company,s ... CEO & Investor Conference at 11:00 a.m. Eastern Time ... access the live audio broadcast or the subsequent archived ...
... , , TUESDAY, Feb. 3 (HealthDay News) -- Mammography use has ... to a new study from the U.S. Centers for Disease ... mammography use increased slightly from 2000 to 2006 in 17 ... fell by 0.3 to 5.3 percent in the 34 states ...
... 5%, study found , , TUESDAY, Feb. 3 (HealthDay News) -- ... of the deadly skin cancer melanoma later in life, a ... born in 1998 in Colorado, asking their parents about childhood ... were age 7 to look for nevi -- commonly known ...
... Volunteers play a critical role in world,s largest ... the coming months, hundreds of Rotary club members ... Korea, the United Kingdom and the Caribbean will ... volunteers and health workers to immunize children against ...
Other Medicine News:Health News:American College of Medical Genetics Foundation Unveils New Website: ACMG Foundation Supports Medical Genetics Research, Education and Practice 2Health News:US Cancer Pain Market to Reach $5 Billion by 2018 - Cancer Patient Growth Drives Value 2Health News:US Cancer Pain Market to Reach $5 Billion by 2018 - Cancer Patient Growth Drives Value 3Health News:Fewer Women Are Having Mammograms 2Health News:Childhood Beach Vacations May Boost Melanoma Risk 2Health News:Rotary Members Worldwide Prepare For Mass Immunization Campaigns In Polio-Endemic Countries 2Health News:Rotary Members Worldwide Prepare For Mass Immunization Campaigns In Polio-Endemic Countries 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: